Adragos and Towa Forge Strategic Partnership to Supply 1.5 Billion Off-Patent Tablets Annually from Japan Facility
核心洞察
Adragos Pharma (搜索) Kawagoe and Towa Pharmaceutical signed a basic agreement to establish a strategic collaboration for stable supply of off-patent pharmaceuticals.
Under the agreement, Adragos will allocate approximately 1.5 billion tablets per year of production capacity to Towa Pharmaceutical from its Kawagoe plant.
Adragos will expand annual solid-dosage capacity at the Kawagoe facility from 1.0 billion to 2.5 billion tablets through staged capital investment.
Adragos Pharma (搜索) Kawagoe has signed a basic agreement with Towa Pharmaceutical to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals in Japan. Under the agreement, Adragos Pharma will promote contract manufacturing utilizing its Kawagoe plant and secure production capacity to supply up to 1.5 billion tablets per year for Towa Pharmaceutical on a planned basis.
The partnership comes at a time when the importance of ensuring a stable supply of off-patent medicines continues to grow in Japan. Adragos Pharma (搜索) believes that pharmaceutical contract manufacturers have an important role to play in supporting a more sustainable supply structure. Through this collaboration, the company aims to contribute to the broader national effort to strengthen domestic manufacturing capacity, production resilience, and long-term supply stability.
Facility Expansion and Capacity Growth
Leveraging this partnership, Adragos Pharma (搜索) will accelerate capital investment at the Kawagoe plant and expand annual solid-dosage capacity from the current 1.0 billion tablets to 2.5 billion tablets in stages. Of this total, capacity of approximately 1.5 billion tablets will be allocated to Towa Pharmaceutical. By sharing demand and supply forecasts, the two companies will work to ensure a stable supply of medicines for the market.
The 16,900 square-meter facility at Kawagoe, located northwest of Tokyo, has a history of more than 50 years of manufacturing and supplying tablets and ampoules for the Japanese market and currently employs over 330 staff.
Leadership Perspectives
Masanori Kurogome, Representative Director of Adragos Pharma (搜索) Kawagoe, emphasized the significance of the collaboration: "Our collaboration with Towa Pharmaceutical represents an important partnership in supporting the stable supply of off-patent medicines. Through capital investment at our Kawagoe plant, we will further strengthen our production and quality assurance systems and, with quality as our highest priority, contribute to a more stable domestic supply of medicines. At the same time, this partnership will support the continued enhancement of our capabilities as a CDMO and our sustainable growth."
Andreas Raabe, Founder and CEO of Adragos Pharma (搜索), added: "This agreement reflects the important role that specialized manufacturing partners can play in supporting the stable supply of medicines. By investing in our Kawagoe site and working closely with Towa Pharmaceutical, we aim to contribute to a stronger and more resilient supply framework for off-patent medicines in Japan."
Strategic Implications for Japan's Pharmaceutical Supply Chain
The collaboration between Adragos and Towa Pharmaceutical represents a significant development in Japan's contract development and manufacturing organization (CDMO) landscape. By securing dedicated production capacity for off-patent medicines, the partnership addresses growing concerns about supply chain vulnerabilities and aims to reinforce domestic pharmaceutical manufacturing infrastructure. The staged capacity expansion to 2.5 billion tablets annually positions the Kawagoe facility as a major production hub for solid-dosage generics in the Japanese market.